NEU 0.35% $20.17 neuren pharmaceuticals limited

Ann: Appendix 4C - quarterly, page-46

  1. 915 Posts.
    lightbulb Created with Sketch. 254
    That’s definitely on the cards I just guess that boils down to how much Acadia wants to “risk”.

    As for the upfront I just think the development costs being substantial (and not fully disclosed yet imo) that chewed into the upfront payments

    For ROW that is removed (somewhat ) . If you look at other territorial licensing deals they follow a similar pattern where the initial upfront is low for the first part of the deal where all development costs are covered. I will revisit some of these to see what the row deal structure looks like
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.